ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis

Will Boggs, MD  |  May 9, 2016

NEW YORK (Reuters Health)—Subcutaneous golimumab every four weeks provides effective long-term maintenance for patients with active ulcerative colitis (UC), according to results from the PURSUIT-SC extension study. The main PURSUIT-M study showed that golimumab treatment maintained clinical responses through Week 54. For most patients, maintenance therapy for UC is required long term. Dr. Peter R….

Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

Michele B. Kaufman, PharmD, BCGP  |  May 4, 2016

A recent Phase 3 study found tofacitinib safe and effective for treating psoriatic arthritis at both 5 mg and 10 mg doses compared with placebo. And the FDA has added label warnings to saxagliptin and alogliptin for an increased risk of heart failure in individuals taking the drugs, particularly in those with heart and kidney disease…

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Reuters Staff  |  May 3, 2016

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

Regeneron Pain Drug Clears Late-Stage Trial

Reuters Staff  |  May 3, 2016

(Reuters)—Drugmaker Regeneron Pharmaceuticals Inc. said on Monday its experimental drug to treat moderate to severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current painkillers. Fasinumab binds to nerve growth factor (NGF) proteins and block their activity,…

France Gets G7 to Discuss Global Regulation of Medicine Prices

Matthias Blamont & Jean-Baptiste Vey  |  May 3, 2016

PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…

Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis

Will Boggs, MD  |  May 3, 2016

NEW YORK (Reuters Health)—The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. “This treatment did seem to have a benefit on axial symptoms,” Dr. Arthur Kavanaugh from the University of California San Diego, La…

Triple Therapy with Methotrexate Effective, Cheaper in RA

Larry Hand  |  April 27, 2016

NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…

Romosozumab Promising for Osteoporosis Treatment; Setbacks for Fulranumab Clinical Trials

Michele B. Kaufman, PharmD, BCGP  |  April 27, 2016

Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…

Abaloparatide May Boost BMD in Older Women with Osteoporosis

Lorraine L. Janeczko  |  April 26, 2016

NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2016

Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…

  • « Previous Page
  • 1
  • …
  • 88
  • 89
  • 90
  • 91
  • 92
  • …
  • 126
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences